VEGF-SPECT with 111In-bevacizumab in stage III/IV melanoma patients

European Journal of Cancer

Volumn 47, Issue 10, 2011, Pages 1595-1602

  Nagengast, Wouter B ^a   Hooge, Marjolijn N Lub De ^a   Van Straten, Esther M E ^a   Kruijff, Schelto ^a   Brouwers, Adrienne H ^a   Den Dunnen, Wilfred F A ^a   De Jong, Johan R ^a   Hollema, Harry ^a   Dierckx, Rudi A ^a   Mulder, Nanno H ^a   De Vries, Elisabeth G E ^a   Hoekstra, Harald J ^a   Hospers, Geke A P ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

Bevacizumab; Biomarker; Imaging; Melanoma; SPECT; VEGF

Indexed keywords

BEVACIZUMAB; FLUORODEOXYGLUCOSE F 18; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; INDIUM; MONOCLONAL ANTIBODY; VASCULOTROPIN A;

ADULT; ARTICLE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MELANOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECURRENT CANCER; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; CHEMISTRY; FEMALE; IMAGE PROCESSING; IMMUNOHISTOCHEMISTRY; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; TIME;

ADULT; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; FEMALE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; IMMUNOHISTOCHEMISTRY; INDIUM RADIOISOTOPES; INFUSIONS, INTRAVENOUS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM METASTASIS; TIME FACTORS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 79958812484     PISSN: 09598049     EISSN: 18790852     Source Type: Journal    
DOI: 10.1016/j.ejca.2011.02.009     Document Type: Article

References (38)

1. J. Folkman What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82 1990 4 6 (Pubitemid 20020880)
2. J. Folkman, and M. Klagsbrun Angiogenic factors Science 235 1987 442 447 (Pubitemid 17009577)
3. N. Ferrara, and T. Davis-Smyth The biology of vascular endothelial growth factor Endocr Rev 18 1997 4 25 (Pubitemid 27076453)
4. H.P. Gerber, and N. Ferrara Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies Cancer Res 65 2005 671 680 (Pubitemid 40216420)
5. J. Gaudreault, D. Fei, J. Rusit, P. Suboc, and V. Shiu Preclinical pharmacokinetics of ranibizumab (rhuFabV2) after a single intravitreal administration Invest Ophthalmol Vis Sci 46 2005 726 733 (Pubitemid 40270359)
6. K. Miller, M. Wang, and J. Gralow Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer N Engl J Med 357 2007 2666 2676
7. A. Sandler, R. Gray, and M.C. Perry Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550 (Pubitemid 44917502)
8. D.H. Gorski, A.D. Leal, and J.S. Goydos Differential expression of vascular endothelial growth factor-A isoforms at different stages of melanoma progression J Am Coll Surg 197 2003 408 418 (Pubitemid 38373300)
9. F. Tas, D. Duranyildiz, and H. Oguz Circulating serum levels of angiogenic factors and vascular endothelial growth factor receptors 1 and 2 in melanoma patients Melanoma Res 16 2006 405 411 (Pubitemid 44511220)
10. 18F] fluorodeoxyglucose positron emission tomography on surgical management of melanoma patients Br J Surg 93 2006 243 249 (Pubitemid 43259613)
11. A. Sekulic, P. Haluska Jr., and A.J. Miller Malignant melanoma in the 21st century: the emerging molecular landscape Mayo Clin Proc 83 2008 825 846 (Pubitemid 351948695)
12. S. Ugurel, G. Rappl, W. Tilgen, and U. Reinhold Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival J Clin Oncol 19 2001 577 583 (Pubitemid 32112873)
13. B. Psaila, and D. Lyden The metastatic niche: adapting the foreign soil Nat Rev Cancer 9 2009 285 293
14. S. Hiratsuka, A. Watanabe, H. Aburatani, and Y. Maru Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis Nat Cell Biol 8 2006 1369 1375 (Pubitemid 44835111)
15. K.A. Varker, J.E. Biber, and C. Kefauver A randomised phase 2 trial of bevacizumab with or without daily low-dose interferon alfa-2b in metastatic malignant melanoma Ann Surg Oncol 14 2007 2367 2376 (Pubitemid 47174913)
16. M. Gonzalez-Cao, S. Viteri, and A. Diaz-Lagares Preliminary results of the combination of bevacizumab and weekly paclitaxel in advanced melanoma Oncology 74 2008 12 16 (Pubitemid 351915004)
17. P. Terheyden, M.A. Hofmann, M. Weininger, E.B. Brocker, and J.C. Becker Anti-vascular endothelial growth factor antibody bevacizumab in conjunction with chemotherapy in metastasising melanoma J Cancer Res Clin Oncol 133 2007 897 901 (Pubitemid 350218914)
18. D.G. Perez, V.J. Suman, and T.R. Fitch Phase 2 trial of carboplatin, weekly paclitaxel, and biweekly bevacizumab in patients with unresectable stage IV melanoma: a North Central Cancer Treatment Group study, N047A Cancer 115 2009 119 127
19. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 2004 581 611 (Pubitemid 39099316)
20. M. Shibuya Vascular endothelial growth factor receptor-2: its unique signaling and specific ligand, VEGF-E Cancer Sci 94 2003 751 756 (Pubitemid 37258771)
21. S.E. Crawford Vascular interference: a blockade to tumor epithelial growth Hepatology 39 2004 1491 1494 (Pubitemid 38702648)
22. N. Ferrara Role of vascular endothelial growth factor in regulation of physiological angiogenesis Am J Physiol Cell Physiol 280 2001 C1358 C1366
23. J.E. Park, G.A. Keller, and N. Ferrara The vascular endothelial growth factor (VEGF) isoforms: differential deposition into the subepithelial extracellular matrix and bioactivity of extracellular matrix-bound VEGF Mol Biol Cell 4 1993 1317 1326 (Pubitemid 24045761)
24. W.B. Nagengast, E.G. De Vries, and G.A. Hospers In vivo VEGF imaging with radiolabelled bevacizumab in a human ovarian tumor xenograft J Nucl Med 48 2007 1313 1319 (Pubitemid 47242797)
25. T.H. Stollman, M.G. Scheer, and W.P. Leenders Specific imaging of VEGF-A expression with radiolabelled anti-VEGF monoclonal antibody Int J Cancer 122 2008 2310 2314 (Pubitemid 351542336)
26. S.K. Chang, I. Rizvi, N. Solban, and T. Hasan In vivo optical molecular imaging of vascular endothelial growth factor for monitoring cancer treatment Clin Cancer Res 14 2008 4146 4153
27. T.H. Stollman, M.G. Scheer, and G.M. Franssen Tumor accumulation of radiolabelled bevacizumab due to targeting of cell- and matrix-associated VEGF-A isoforms Cancer Biother Radiopharm 24 2009 195 200
28. M.G. Scheer, T.H. Stollman, and O.C. Boerman Imaging liver metastases of colorectal cancer patients with radiolabelled bevacizumab: lack of correlation with VEGF-A expression Eur J Cancer 44 2008 1835 1840
29. W.B. Nagengast, M.A. de Korte, and T.H. Oude Munnink 89Zr-bevacizumab PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVP-AUY922 J Nucl Med 51 2010 761 767
30. http://www.nccn.org/professionals/physician-gls/f-guidelines.asp.
31. A.M. Loening, and S.S. Gambhir AMIDE: a free software tool for multimodality medical image analysis Mol Imaging 2 2003 131 137
32. G.C. Jayson, J. Zweit, and A. Jackson Molecular imaging and biological evaluation of HuMV833 anti-VEGF antibody: implications for trial design of antiangiogenic antibodies J Natl Cancer Inst 94 2002 1484 1493 (Pubitemid 35251753)
33. D.R. Collingridge, V.A. Carroll, and M. Glaser The development of [(124)I]iodinated-VG76e: a novel tracer for imaging vascular endothelial growth factor in vivo using positron emission tomography Cancer Res 62 2002 5912 5919 (Pubitemid 35204754)
34. P.J. Perik, M.N. Lub-De Hooge, and J.A. Gietema Indium-111-labeled trastuzumab scintigraphy in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer J Clin Oncol 24 2006 2276 2282 (Pubitemid 46630657)
35. L. Jilaveanu, C. Zito, and S.J. Lee Expression of sorafenib targets in melanoma patients treated with carboplatin, paclitaxel and sorafenib Clin Cancer Res 15 2009 1076 1085
36. O. Straume, and L.A. Akslen Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas Am J Pathol 159 2001 223 235 (Pubitemid 33704207)
37. J.P. O'Connor, R.A. Carano, and A.R. Clamp Quantifying antivascular effects of monoclonal antibodies to vascular endothelial growth factor: insights from imaging Clin Cancer Res 15 2009 6674 6682
38. C.G. Willett, Y. Boucher, and E. di Tomaso Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer Nat Med 10 2004 145 147 (Pubitemid 38524883)